SCM
KYMR icon

Silverarc Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Silverarc Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-34,589
Closed -$2.69M – 80
2025
Q4 		$2.69M Buy
+34,589
New +$2.34M 0.37% 54

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Silverarc Capital Management's KYMR Position: Q1 2026 in Review

Silverarc Capital Management sold out of Kymera Therapeutics (KYMR) in Q1 2026, closing a stake of 34,589 shares — an estimated $2.69M sold.

Silverarc Capital Management first reported a position in KYMR in Q4 2025 and held it in 1 quarter. The position peaked at $2.69M in Q4 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Silverarc Capital Management reported no remaining Kymera Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Silverarc Capital Management sold 34,589 Kymera Therapeutics shares in Q1 2026, an estimated $2.69M.
  • Silverarc Capital Management first reported a position in Kymera Therapeutics in Q4 2025 and held it in 1 quarter.
  • Silverarc Capital Management's Kymera Therapeutics position peaked at $2.69M in Q4 2025.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.